← All trials
NCT03671044
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 10, 2018
- Primary completion
- Mar 31, 2022
- Completion date
- May 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 657
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jina Pharmaceuticals, Inc.Lead sponsor
- Intas Pharmaceuticals LimitedCollaborator
- Lambda Therapeutic Research LtdStudy chair
- Lambda Therapeutic Research LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.